ERBB2 and cancer: In view of their drug mechanisms which bind to the HER2 kinase domain, pyrotinib or lapatinib can be a potential option for cancer patients with ERBB2 fusions, especially those X-ERBB2 fusions, which needs to be prospectively explored.